The Breast Oncology Program at the Susan F. Smith Center for Women's Cancers at Dana-Farber provides state-of-the-art and compassionate care for breast cancer patients. Our breast cancer clinicians are committed to providing your patients with the best and most individualized treatment options available, including the latest medical oncology, surgical options, breast reconstruction, and radiation therapy.
Our focused and specialized services include programs for: young adults with breast cancer, metastatic breast cancer, inflammatory breast cancer, breast cancer during pregnancy, breast and ovarian cancer genetics and prevention, older adults with breast cancer, patients with breast cancer brain metastases, breast cancer in men, and ductal carcinoma in situ (DCIS).
Featured Content |view more
News
Rethinking Breast Cancer: Illuminating New Paths to Treatment and Prevention
Clinical trial data can often help scientists find answers in their quest to treat cancers. Sometimes, it can also reveal surprising new evidence about the drivers of disease, illuminating a new tactic for preventing cancer in the first place.
News
A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found.
Document
Patients With a History of Breast Cancer who Desire Pregnancy
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations for patients with a history of breast cancer who desire pregnancy.
News
Most Young Women Treated For Breast Cancer Can Have Children, Study Shows
In a study of nearly 200 young women who have survived breast cancer, most of those who tried to conceive were able to become pregnant and give birth.
News
Breast Cancer Trial Aims to Improve Treatment for Men
Over the past 30 years, outcomes have improved dramatically for women with breast cancer. There are many new treatments, including hormone therapies and CDK4/6 inhibitors. In contrast, there has been no improvement in the outcomes for ...
News
Antibody-Drug Conjugates: A Cancer Therapy Revolution
Dana-Farber researchers explore how a novel therapy may benefit patients
